Overview
NICE is unable to make a recommendation on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer in adults who have had anti-androgen treatment but have not had a taxane. This is because the company did not provide an evidence submission.
Last reviewed: 16 July 2026
Next review: We will review this decision if the company decides to make a submission.